Global pharmaceutical leader Novartis announced the rollout of Coartem Baby (artemether-lumefantrine), the first-ever malaria treatment specifically formulated for newborns and young infants, which has now secured regulatory approval across 16 countries. Alongside this pediatric milestone, the company completed regulatory submissions to the U.S. FDA and Swissmedic for KLU156 (ganaplacide/lumefantrine), a next-generation antimalarial candidate granted priority review. Public health experts note that infant-tailored dosing will dramatically improve survival rates in malaria-endemic regions.
About the Author
